Literature DB >> 30660352

Alarming Increasing Trends in Hospitalizations and Mortality With Heyde's Syndrome: A Nationwide Inpatient Perspective (2007 to 2014).

Rupak Desai1, Tarang Parekh2, Sandeep Singh3, Upenkumar Patel4, Hee Kong Fong5, Dipen Zalavadia6, Sejal Savani7, Rajkumar Doshi8, Rajesh Sachdeva9, Gautam Kumar10.   

Abstract

We studied the trends and outcomes of patients with intestinal angiodysplasia-associated gastrointestinal bleeding (Heyde's syndrome [HS]) with aortic stenosis (AS) who underwent surgical aortic valve replacement (SAVR) versus transcatheter aortic valve implantation (TAVI). The National Inpatient Sample (2007 to 2014) and International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to identify HS hospitalizations, pertinent co-morbidities, and outcomes of SAVR versus TAVI from 2011 to 2014. The incidence of HS with AS was 3.1%. The trends in hospitalizations and all-cause inpatient mortality showed relative surges of 29.16% (from 48 to 62 per 100,000) and 22.7% (from 3.7 to 4.54 per 100,000) from 2007 to 2014. HS patients were older (mean age ∼80 vs 77 years) females (54.3% vs 52.2%) compared with AS without HS. The all-cause mortality (6.9% vs 4.1%), length of stay (LOS) (∼7.0 vs 5.8 days), and hospitalization charges ($58,519.31 vs $57,598.67) were higher in HS (p<0.001). No differences were reported in all-cause mortality and hospital charges in HS patients who underwent either SAVR or TAVI. However, the TAVI cohort showed lower rates of stroke (1.7% vs 10.0%) and blood transfusion (1.7% vs 11.7%), a shorter LOS (18.3 vs 23.9 days; p<0.001), and more routine discharges (21.7% vs 14.8%, p = 0.01). An older age, male gender, Asian race, congestive heart failure, coagulopathy, fluid and/or electrolytes disorders, chronic pulmonary disease, and renal failure raised the odds of mortality in HS patients. In conclusion, we observed increasing rates of hospitalizations with HS and higher inpatient mortality from 2007 to 2014. The HS patients who underwent TAVI had fewer complications without any difference in the all-cause mortality compared with SAVR.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Year:  2019        PMID: 30660352     DOI: 10.1016/j.amjcard.2018.12.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Heyde's Syndrome Complicating Management in a Patient With High Bleeding and Thrombotic Risks.

Authors:  Talha Ahmed; Reyaz Haque
Journal:  Cureus       Date:  2020-05-25

Review 2.  Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status.

Authors:  Antonio Greco; Davide Capodanno
Journal:  Interv Cardiol       Date:  2020-04-23

3.  A Nationwide Assessment of the "July Effect" and Predictors of Post-Endoscopic Retrograde Cholangiopancreatography Sepsis at Urban Teaching Hospitals in the United States.

Authors:  Rupak Desai; Upenkumar Patel; Shreyans Doshi; Dipen Zalavadia; Wardah Siddiq; Hitanshu Dave; Mohammad Bilal; Vikas Khullar; Hemant Goyal; Madhav Desai; Nihar Shah
Journal:  Clin Endosc       Date:  2019-05-27

4.  Secondary angiodysplasia-associated gastrointestinal bleeding in end-stage renal disease: Results from the nationwide inpatient sample.

Authors:  Tooba Tariq; Patrick Karabon; Furqan B Irfan; Sachin Goyal; Matthew Masaru Mayeda; Austin Parsons; Stephanie Judd; Murray Ehrinpreis
Journal:  World J Gastrointest Endosc       Date:  2019-10-16

5.  Heyde's Syndrome - An Enigma.

Authors:  Fayaz Mohammed Khazi; Nayyer R Siddiqi; Yehia Mohamed Karaly; Obaid Aljassim; Zohair Y Al-Halees
Journal:  J Saudi Heart Assoc       Date:  2020-12-14

6.  Heyde syndrome: prevalence and outcomes in patients undergoing transcatheter aortic valve implantation.

Authors:  Lara Waldschmidt; Andreas Drolz; Paula Heimburg; Alina Goßling; Sebastian Ludwig; Lisa Voigtländer; Matthias Linder; Niklas Schofer; Hermann Reichenspurner; Stefan Blankenberg; Dirk Westermann; Lenard Conradi; Johannes Kluwe; Moritz Seiffert
Journal:  Clin Res Cardiol       Date:  2021-07-23       Impact factor: 5.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.